Caisse DE Depot ET Placement DU Quebec Acquires 263,570 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Caisse DE Depot ET Placement DU Quebec lifted its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 280.4% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 357,579 shares of the biopharmaceutical company's stock after acquiring an additional 263,570 shares during the quarter. Caisse DE Depot ET Placement DU Quebec owned 0.28% of Halozyme Therapeutics worth $17,096,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in HALO. Vanguard Group Inc. boosted its position in Halozyme Therapeutics by 3.0% during the fourth quarter. Vanguard Group Inc. now owns 13,281,714 shares of the biopharmaceutical company's stock valued at $634,999,000 after buying an additional 386,618 shares during the period. Snyder Capital Management L P lifted its stake in shares of Halozyme Therapeutics by 2.6% in the 4th quarter. Snyder Capital Management L P now owns 4,168,453 shares of the biopharmaceutical company's stock valued at $199,294,000 after acquiring an additional 105,086 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in Halozyme Therapeutics by 2.5% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,933,560 shares of the biopharmaceutical company's stock valued at $92,446,000 after acquiring an additional 47,795 shares during the period. Northern Trust Corp grew its position in Halozyme Therapeutics by 8.7% during the 4th quarter. Northern Trust Corp now owns 1,827,771 shares of the biopharmaceutical company's stock worth $87,386,000 after acquiring an additional 145,617 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its position in Halozyme Therapeutics by 0.6% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,783,177 shares of the biopharmaceutical company's stock worth $85,254,000 after acquiring an additional 9,780 shares during the last quarter. Hedge funds and other institutional investors own 97.79% of the company's stock.

Halozyme Therapeutics Stock Down 0.9 %

HALO traded down $0.57 on Monday, hitting $60.62. The company had a trading volume of 905,972 shares, compared to its average volume of 1,441,790. The stock has a fifty day simple moving average of $60.85 and a 200-day simple moving average of $55.46. The company has a debt-to-equity ratio of 4.14, a current ratio of 7.80 and a quick ratio of 9.15. The firm has a market capitalization of $7.49 billion, a P/E ratio of 17.67, a P/E/G ratio of 0.42 and a beta of 1.26. Halozyme Therapeutics, Inc. has a 52-week low of $40.19 and a 52-week high of $66.00.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last released its earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 EPS for the quarter, beating analysts' consensus estimates of $1.17 by $0.02. The company had revenue of $298.01 million during the quarter, compared to analysts' expectations of $285.74 million. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. As a group, equities analysts expect that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on HALO shares. HC Wainwright reissued a "buy" rating and set a $72.00 price objective on shares of Halozyme Therapeutics in a research note on Friday, April 25th. Piper Sandler increased their price target on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a "neutral" rating in a research report on Friday, January 10th. JPMorgan Chase & Co. boosted their price objective on shares of Halozyme Therapeutics from $55.00 to $58.00 and gave the company a "neutral" rating in a research report on Monday, April 21st. Benchmark reaffirmed a "buy" rating and set a $75.00 price objective on shares of Halozyme Therapeutics in a research note on Thursday, February 20th. Finally, Wells Fargo & Company reduced their price target on Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating on the stock in a report on Monday, January 13th. Four analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, Halozyme Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus target price of $62.89.

Insider Buying and Selling

In other news, Director Jeffrey William Henderson sold 503 shares of the firm's stock in a transaction on Tuesday, April 1st. The stock was sold at an average price of $64.05, for a total transaction of $32,217.15. Following the completion of the transaction, the director now directly owns 33,108 shares in the company, valued at $2,120,567.40. This trade represents a 1.50 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Michael J. Labarre sold 10,000 shares of the company's stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $58.05, for a total transaction of $580,500.00. Following the completion of the transaction, the senior vice president now owns 185,453 shares in the company, valued at approximately $10,765,546.65. The trade was a 5.12 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 21,697 shares of company stock worth $1,276,552 in the last three months. 2.40% of the stock is owned by corporate insiders.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.